scispace - formally typeset
Search or ask a question
Author

Johannes Wogatzky

Bio: Johannes Wogatzky is an academic researcher. The author has contributed to research in topics: Bromocriptine & Semen quality. The author has an hindex of 3, co-authored 6 publications receiving 76 citations.

Papers
More filters
Journal ArticleDOI
TL;DR: Combinations of adverse lifestyle factors could have a detrimental impact on sperm, not only in terms of motility and sperm count but also in Terms of sperm head vacuolization.
Abstract: Background Poor sperm quality can negatively affect embryonic development and IVF outcome. This study is aimed at investigating the influence of various lifestyle factors on semen quality according to MSOME (motile sperm organelle morphology examination) criteria.

54 citations

Journal ArticleDOI
TL;DR: In this paper, the frequency and severity of ovarian hyperstimulation syndrome and the pregnancy rate in a patient collective at risk who received bromocriptine treatment were investigated and a retrospective study was conducted.

18 citations

Journal Article
TL;DR: It is suggested that andullation therapy prior to blastocyst transfer in a cryo-cycle improves embryo implantation, most likely due to a reduction in stress (ie, a relaxation effect on patients), a Reduction in uterine contractions, and, probably, an enhancement of the blood flow in the abdominal region.
Abstract: ContextMassage therapy is increasingly used to relieve physical and mental discomfort and is suggested as a safe therapeutic modality, without any significant risks or any known side effects. Although a multitude of complementary therapies, such as acupuncture, are applied in reproductive medicine, no information is available with regard to the application of massage as an adjuvant therapy in assisted- reproduction techniques (ARTs). ObjectivesThis study was intended to assess the effectiveness of a deep relaxation (andullation) therapy based on oscillating vibrations when used prior to embryo transfer (ET) in in vitro fertilization (IVF) cryo-cycles. DesignThe research team designed a retrospective, observational study. Participants willing to undergo the massage treatment were allocated to the intervention (andullation) group. SettingThe study was performed at the IVF Centers Prof. Zech-Bregenz in Bregenz, Austria. ParticipantsA total of 267 IVF patients, with a mean age of 36.3 y, participated in this single-center study. InterventionAll patients receiving a transfer of vitrified and warmed blastocysts between January and December 2012 were included in the evaluation. Prior to ET, the andullation group received a standardized program of therapy—a 30-min, deep relaxation massage on an oscillating (vibrating) device, whereas the control group did not. Outcome MeasuresTo determine efficacy, the primary outcomes that the study measured were (1) pregnancy rates (PRs), by testing urine and obtaining a positive β-human chorionic gonadotropin (β-hCG); and (2) ongoing, pregnancies (oPR), by observation of fetal heartbeat and birth rates (BR) as well as miscarriage rates. The patients' medical histories and types of infertility as well as the quality of the embryo transfers (ETs) were evaluated. ResultsIn patients using the massage therapy prior to ET, significantly higher PRs, oPRs, and BRs were observed compared with the control group—PR: 58.9% vs 41.7%, P < .05; oPR: 53.6% vs 33.2%, P < .01; and BR: 32.0% vs 20.3%, P < .05. No differences were detected among groups for patients' ages, hormonal substitution protocols, endometrium structures and buildups, quality of transferred embryos, or quality of transfers. No adverse effects were noted in the massage group. ConclusionsThe research team's results suggested that andullation therapy prior to blastocyst transfer in a cryo- cycle improves embryo implantation, most likely due to a reduction in stress (ie, a relaxation effect on patients), a reduction in uterine contractions, and, probably, an enhancement of the blood flow in the abdominal region. These findings provide support for use of andullation as a complementary therapy for ART. (Altern Ther Health Med. 2015;21(2):16-22.)

14 citations

Journal ArticleDOI
TL;DR: A significant increase in the blastocyst rate and demonstrated a substantial rise in ongoing pregnancy rate of the supplemented patients and the outcome of the micronutrient supplemented patients corresponded to the average of healthy IVF patients without HT at the authors' clinic.
Abstract: In Assisted Reproduction Techniques (ART), autoimmune disorders of the thyroid gland present as common concomitant diseases. Hypothyroidism caused by autoimmune thyroiditis can impair fertility and pregnancy. Hashimoto thyroiditis (HT) is the most common autoimmune thyroid disease (AITD). Patients with HT undergoing IVF/ICSI using the long protocol are thought to benefit from a broad therapeutic concept. We compared the outcome of two different therapeutic schemes for HT patients presenting at our fertility clinic and compared the outcome to ART patients without thyroiditis. TSH level was adjusted to under 2 µIU/mL using L-thyroxine, as required. Concurrent medication from the time of oocyte puncture included daily administration of fragmin (dalteparin) and acetylsalicylic acid (ASA), as well as prednisolone in increasing dosage. One group of these HT patients (group1, n=56) had additionally highly-dosed folic acid, another group (group 2, n=50, referred to as the supplemented group) was alternatively supplemented with a micronutrient preparation containing selenium, high-dose folic acid, B-vitamins, antioxidants and iron. We compared the number of oocytes, fertilization rate, blastocyst formation rate, pregnancy- and ongoing pregnancy rate between the two groups. Also, the ART outcomes of both groups were compared to ART results of non-HT patients within the same age group. We observed a significant increase in the blastocyst rate and demonstrated a substantial rise in ongoing pregnancy rate of the supplemented patients. These also needed less L-thyroxine to achieve optimal TSH level. The outcome of the micronutrient supplemented patients corresponded to the average of healthy IVF patients without HT at our clinic.

1 citations

01 Jan 2011
TL;DR: The aim of this retrospective study is to investigate the frequency and severity of ovarian hyperstimulation syndrome and the pregnancy rate in a patient collective at risk who received bromocriptine treatment.
Abstract: Vascularendothelialgrowthfactor(VEGF)increasescapillarypermeability . It is pathophysiological associated with the accumulation of third-space fluid and is directly involved in the development of ovarian hyperstimulation syndrome (OHSS). In women with OHSS, increased VEGF levels are expressed in the granulosa cells; the concentration correlates with the severity of OHSS(1).Vascularendothelialcadherin,atransmembraneprotein whose release is associated with higher concentrations of VEGF and hCG, causes loss of endothelial architecture (2). Gomez et al. (3) found that 80 genes were upregulated and seven were downregulated in OHSS in their study of gene expression profiles in animals. Because tyrosine hydroxylase is downregulated and reduces the synthesis of dopamine, it led to increased vascular permeability in animal studies (3). A significant reduction of vascular permeability was achieved using D2 dopamine agonists. Dopamine agonists prevent the phosphorylation of VEGF receptor 2 and reduce the in vitro and in vivo release of vasoactiveangiogenic agents. As a result, vascular permeability is also reduced (2, 4). Dopamine receptor binding is dose dependent (i.e., high doses block angiogenesis); however, low doses do not promote antiangiogenic activity(5). The dopamine agonists cabergoline, quinagolide, and bromocriptine stimulate the dopamine D2 receptor. There are several studies showing that cabergoline (Dostinex, Cabersil) or quinagolide (Norprolac) can reduce the incidence of OHSS (5–10). However, there are currently no publications demonstrating the effectiveness of bromocriptine (Parlodel, Pravidel). The advantages of bromocriptine are its lower half-life and the greater experience with this drug in pregnancy.Repeatedoccurrenceofseverefibroticcardiacvalvulopathy in conjunction with the use of cabergoline did, however, raise concerns leading to the withdrawal of this substance from the U.S. market in 2007.

1 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: It is suggested that greater focus on collection of DNA fragmentation and progressive motility in a clinical setting may lead to better patient outcomes during fertility treatments of aging couples, even though sperm concentration did not decline with increasing male age.

257 citations

Journal ArticleDOI
TL;DR: Functional magnetic resonance imaging data have suggested that moderate pressure massage was represented in several brain regions including the amygdala, the hypothalamus and the anterior cingulate cortex, all areas involved in stress and emotion regulation.

254 citations

Journal ArticleDOI
TL;DR: Results showed that alcohol intake has a detrimental effect on semen volume and normal morphology, and studies evaluating the effect of changes on semen parameters on the reproductive outcomes are needed in advance of providing recommendations regarding alcohol intake other than the advice to avoid heavy alcohol drinking.
Abstract: Alcohol consumption is widespread in the Western world. Some studies have suggested a negative association between alcohol intake and semen quality although others have not confirmed this. MEDLINE and Embase were searched using ‘alcohol intake' OR ‘alcohol consumption' OR ‘alcohol drinking' OR ‘lifestyle' combined with ‘semen quality' OR ‘sperm quality' OR ‘sperm volume' OR ‘sperm concentration' OR ‘sperm motility' for full-length observational articles, published in English. Reference lists of retrieved articles were searched for other pertinent studies. Main outcome measures were sperm parameters, if provided as means (standard deviation or standard error) or as medians (interquartile range). Fifteen cross-sectional studies were included, with 16,395 men enrolled. Main results showed that alcohol intake has a detrimental effect on semen volume (pooled estimate for no/low alcohol consumption 0.25 ml, 95% CI, 0.07 to 0.42) and normal morphology (1.87%, 95% CI, 0.86 to 2.88%). The difference was more marked when comparing occasional versus daily consumers, rather than never versus occasional, suggesting a moderate consumption did not adversely affect semen parameters. Hence, studies evaluating the effect of changes on semen parameters on the reproductive outcomes are needed in advance of providing recommendations regarding alcohol intake other than the advice to avoid heavy alcohol drinking.

125 citations

Reference EntryDOI
TL;DR: Cabergoline appears to reduce the risk of OHSS in high-risk women, especially for moderate OHSS, and the use of cabergoline does not affect the pregnancy outcome, nor is there an increased risk of adverse events.
Abstract: Background Ovarian hyperstimulation syndrome (OHSS) is a complication resulting from administration of human chorionic gonadotrophin (hCG) in assisted reproduction technology (ART) treatment. Most case are mild, but forms of moderate or severe OHSS appear in 3% to 8% of in vitro fertilisation (IVF) cycles. Recently, the dopamine agonist cabergoline has been introduced as a secondary prevention intervention for OHSS in women at high risk of OHSS who are undergoing ART treatment. Objectives To assess the effectiveness and safety of cabergoline in preventing ovarian hyperstimulation syndrome (OHSS) in high-risk women undergoing ART treatment. Search methods Major medical databases (Cochrane Menstrual Disorders and Subfertility Group Specialised Register of trials, CENTRAL (The Cochrane Library), MEDLINE, EMBASE and PsycINFO) were systematically searched for randomised controlled trials (RCTs) assessing the effect of cabergoline in preventing OHSS. Databases were searched up to September 2011. Registers of clinical trials, abstracts of scientific meetings and reference lists of included studies were searched. No language restrictions were applied. Selection criteria RCTs which compared cabergoline with placebo, no treatment or another intervention for preventing OHSS in high-risk women were considered for inclusion. Primary outcome measures included incidence of moderate or severe OHSS and live birth rate. Secondary endpoints were clinical pregnancy rate, multiple pregnancy rate, miscarriage rate and any other adverse effects of the treatment. Data collection and analysis Two authors independently screened titles, abstracts and the full text of publications; extracted data; and assessed risk of bias. Any disagreements were resolved by consensus. Pooled results were reported as odds ratio (OR) and 95% confidence interval (95% CI) by the Mantel-Haenszel method. Main results Only two trials involving 230 women met the inclusion criteria. Both studies had a moderate risk of bias. Oral cabergoline, 0.5 mg daily, was given as an intervention and compared with a matched placebo. A statistically significant reduction in OHSS was observed in the cabergoline treated group (OR 0.40, 95% CI 0.20 to 0.77; 2 RCTs, 230 women) with a number needed to treat (NTT) of 7. There was a statistically significant difference in the incidence of moderate OHSS, favouring cabergoline (OR 0.38, 95% CI 0.19 to 0.78; 2 RCTs, 230 women) but not in severe OHSS (OR 0.77, 95% CI 0.24 to 2.45; 2 RCTs, 230 women). There was no significant difference in the clinical pregnancy rate (OR 0.94, 95% CI 0.56 to 1.59; 2 RCTs, 230 women), miscarriage rate (OR 0.31, 95% CI 0.03 to 3.07; 1 RCT, 163 women) or any other adverse effects of the treatment (OR 2.07, 95% CI 0.56 to 7.70; 1 RCT, 67 women). However, no data on multiple pregnancy rate or live birth rate were reported in either trial. Authors' conclusions Cabergoline appears to reduce the risk of OHSS in high-risk women, especially for moderate OHSS. The use of cabergoline does not affect the pregnancy outcome (clinical pregnancy rate, miscarriage rate), nor is there an increased risk of adverse events. Further research should consider the risk of administering cabergoline and the comparison between cabergoline and established treatments (such as intravenous albumin and coasting). Large, well-designed and well-executed RCTs that involve more clinical endpoints are necessary to further evaluate the role of cabergoline in OHSS prevention.

106 citations